Brought to you by 
Medtronic to buy Osteotech for about $118mm
20 Aug 2010
Executive Summary
To expand its regenerative biologics offerings, Medtronic Inc. is paying $6.50 in cash (a 74% premium) for each outstanding share of fellow public device company Osteotech Inc., valuing the transaction at about $118mm.
Deal Industry
- Biotechnology
- Medical Devices
-
Medical Devices
- Biomaterials
- Implantable Devices
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com